ARTICLE | Clinical News
Xifaxan rifaximin regulatory update
August 16, 2010 7:00 AM UTC
FDA accepted for filing and granted Priority Review to an sNDA from Salix for Xifaxan rifaximin 550 mg tablets to treat non-constipation irritable bowel syndrome (IBS) and IBS-related bloating. The PD...